Myovant Sciences's revenue per share for the
three
months ended in Mar. 2022 was $0.61.
Myovant Sciences's revenue per share for the trailing twelve months (TTM) ended in Mar. 2022 was $2.48.
During the past 12 months, the average Revenue Per Share Growth Rate of Myovant Sciences was 276.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.
The historical rank and industry rank for Myovant Sciences's Revenue per Share or its related term are showing as below:
Myovant Sciences Revenue per Share Historical Data
The historical data trend for Myovant Sciences's Revenue per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Myovant Sciences Annual Data
Trend
Mar16
Mar17
Mar18
Mar19
Mar20
Mar21
Mar22
Revenue per Share
-
-
-
0.66
2.48
Myovant Sciences Quarterly Data
Jun17
Sep17
Dec17
Mar18
Jun18
Sep18
Dec18
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Revenue per Share
0.27
0.45
0.84
0.58
0.61
Myovant Sciences Revenue per Share Calculation
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Myovant Sciences's Revenue Per Share for the fiscal year that ended in Mar. 2022 is calculated as
Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.48
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Myovant Sciences (NYSE:MYOV) Revenue per Share Explanation
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Myovant Sciences Revenue per Share Related Terms
Thank you for viewing the detailed overview of Myovant Sciences's Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Myovant Sciences Ltd is a healthcare company focused on redefining care for women and for men. The company's lead product candidate is relugolix, a once-daily, oral GnRH receptor antagonist. It has three late-stage clinical programs for relugolix in uterine fibroids, endometriosis, and prostate cancer. The company is also developing MVT-602, an oligopeptide kisspeptin-1 receptor agonist, that has completed a Phase 2a study for the treatment of female infertility as part of assisted reproduction.
My Portfolios
Create New Portfolio
Portfolio Contest
My Gurus
Personalize
Premium Gurus 
0.07(0.72%) Volume: 186,420 1:20PM EDT
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP
NYSE:MYOV has been successfully added to your 
